KDR and breast carcinoma: In pancreatic neuroendocrine tumor (RT2-PNET), mammary carcinoma (MMTV-PyMT), and glioblastoma (NFpp10-GBM) [97] mouse models, therapy based on anti-VEGFR2 and anti-PD-L1 normalized tumor vessels, favoring the intertumoral infiltration of activated T cells.